Semaglutide weight loss near me

Semaglutide weight loss near me

 

 

Semaglutide weight loss near me Program uses compounded semaglutide, a GLP-1 receptor agonist, in a 1ml bottle for subcutaneous injection to support chronic weight management. Available through telehealth platforms like Henry Meds or WeightCare, it’s prescribed for adults with a BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities (e.g., hypertension, type 2 diabetes). Not FDA-approved, it’s compounded to address shortages or affordability, unlike brand-name Wegovy (2.4mg).

 

how does semaglutide work for weight loss

 

Mechanisms of Action
Semaglutide mimics the GLP-1 hormone, stimulating insulin release, slowing gastric emptying, and suppressing appetite via brain signaling. This reduces hunger and caloric intake, promoting fat loss. The 1ml bottle (e.g., 5mg/ml concentration) allows flexible dosing, typically starting at 0.25mg weekly. Phase 3 STEP trials showed 14.9–20% weight loss with 2.4mg semaglutide over 68 weeks, with compounded versions showing comparable results in practice.

 

 

semaglutide dosing for weight loss

 

 

Weight Loss: Achieves 10–15% body weight loss (20–30 lbs for a 200-lb person) over 6–12 months with diet and exercise.

 

Appetite Control: Reduces cravings within 2–4 weeks, aiding adherence to 1,200–1,800 kcal/day diets.

 

Metabolic Health: Improves blood pressure, lipids, and insulin sensitivity.

 

semaglutide tablets for weight loss

 

 

Cardiovascular Benefits: Lowers heart attack/stroke risk in at-risk adults.
Users report 5–10% loss in 12 weeks with lifestyle changes.

Dosage and Administration
Start with 0.05ml (0.25mg) weekly for 4 weeks, injected into the abdomen, thigh, or upper arm, rotating sites. Increase to 0.1ml (0.5mg) for weeks 5–8, titrating up to 0.5ml (2.5mg) as tolerated. Use a new needle per dose; store refrigerated (36–46°F). Administer with 150 min/week exercise and a 500 kcal/day deficit diet.

Safety and Side Effects
Common side effects include nausea, diarrhea, and constipation (20–40%), most intense during dose escalation. Serious risks include pancreatitis, gallbladder issues, and thyroid tumors (seen in rats). Avoid in medullary thyroid carcinoma or MEN2 history. Not for pregnant/breastfeeding women. Monitor for severe abdominal pain or thyroid symptoms.

Legal Status
Prescription-only from compounding pharmacies; not FDA-approved. Banned by WADA. Obtain from reputable sources like Henry Meds.